UNSPSC 51161712: Almitrine

This classification denotes a cns stimulant with the molecular formula C26H29F2N7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9A1222NBG4, chemically known as 1,3,5-triazine-2,4-diamine, 6-(4-(bis(4-fluorophenyl)methyl)-1-piperazinyl)-n,n-di-2-propenyl- but generally known as almitrine, which bears US NIH Compound Identifier 33887. Almitrine comes in various forms, including bismesylate, bismethane sulfonate, dimesylate, dimethanesulfonate, and mesylate.

UNSPSC 51161712 Almitrine is a Commodity code that sits at the lowest level of the taxonomy; however, the recent state and local solicitations tagged under this code do not reflect procurement of almitrine itself, but rather a broader set of pharmaceutical and pharmacy-related services and products including naloxone, safe drug deactivation systems, on-site pharmacy operations, and generic multi-source pharmaceuticals. State and local governments are using this code to acquire pharmaceutical supplies, pharmacy benefit administration, direct-to-manufacturer prescription programs, and over-the-counter products through health departments, county health systems, and cooperative purchasing vehicles. The issuing bodies span county health departments (Seminole County, Florida and Hall County, Georgia), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota and Oregon). These jurisdictions are procuring pharmaceuticals and pharmacy services to support community health initiatives, employee group health plans, and Medicaid or state health program populations.

Recent activity appears concentrated in the Southeast and Midwest, with Seminole County and Hall County in Florida and Georgia issuing separate solicitations in mid-2026, Texas HHS posting a Request for Information in April 2026, and MMCAP (Minnesota Department of Administration) issuing a multistate RFP in January 2026 due March 26, 2026. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026. Hall County, Georgia issued RFQ/P #47-010 on May 4, 2026, for on-site pharmacy services at its Family Health Center Clinic in Gainesville, serving approximately 3,005 enrolled individuals with an June 4, 2026 proposal deadline. MMCAP's multistate RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, requires vendors to work through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) and emphasizes price competitiveness at 75 percent of the evaluation score. The Texas RFI on direct-to-manufacturer prescriptions functions as preliminary market intelligence rather than a formal competitive solicitation.